ArticleCellular and molecular life sciences : CMLS2026
The bile acid TUDCA promotes chemoresistance and predicts survival through MAPK signaling in pancreatic ductal adenocarcinoma.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Our study comprehensively investigated the prognostic significance and biological mechanisms of bile acids in patients with advanced pancreatic adenocarcinoma (PC) through clinical data analysis, in vitro cell assays, and in vivo xenograft models. A total of 101 patients with advanced pancreatic adenocarcinoma were followed up in this study. Multivariate Cox regression identified elevated total bile acids (tBA) as an independent risk factor for progression-free survival (PFS). Patients with high tBA exhibited significantly shorter PFS and overall survival (OS), alongside impaired liver function and an immunosuppressive profile. Bile acid mass spectrometry further identified tauro-ursodeoxycholic acid (TUDCA) as a key subtype strongly associated with poor survival and a diminished response to first-line gemcitabine-based chemotherapy. ROC analysis confirmed that TUDCA outperformed tBA and other clinical indicators in predicting treatment outcomes. Mechanistically, TUDCA did not affect pancreatic cancer cell proliferation but significantly attenuated gemcitabine-induced cytotoxicity both in vitro and in vivo by inhibiting apoptosis. RNA sequencing and western blot analyses revealed that TUDCA confers chemoresistance by activating the MAPK signaling pathway. Notably, the MEK1/2 inhibitor trametinib successfully reversed TUDCA-mediated resistance in experimental models. These findings identify TUDCA as a novel prognostic biomarker and a potential therapeutic target to enhance chemotherapy efficacy in advanced PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.